- 英文名称
- (S)-Mirtazapine
- 分子式
- C17H19N3
- 分子量
- 265.35
- 中文别名
- 米氮平杂质23; (+)-Mirtazapine; (14bS)-2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; (14b,S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; (S)-mirtazepine; (S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; Esmirtazapine; ORG-50081; (S)-(+)-MIRTAZAPINE; (S)-1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; (S)-1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3c][2]benzazepine; (S)1,2,3,4,10,14b-hexahydro-2-methyl-pyrazino-[2,1-a] pyrido [2,3-c] [2] benzazepin; (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; (+)-(S)-Mirtazapine; (14bS)-1,2,3,4,10,14bα-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; (S)-6-Azamianserin; S-(+)-Mirtazapine
- 用途
- 作为Mirtazapine的S(+)-对映异构体，在急性热伤害感受动物模型中具有促伤害感受的特性；是立体选择性5-HT2受体拮抗剂，在体内被CYP2D6和CYP1A2代谢；靶点为5-HT2受体、5-HT3受体
